University of Cambridge

Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. "It's a pleasure to welcome Sohanya to our Board," said Sanford Zweifach, Chair of the Carisma Board. "Her broad experience in oncology, alongside her skills in leadership, strategic planning, and commercialization, will be instrumental as we continue to advance our portfolio and strengthen our foundation. We are also thankful to Michael for his valuable service and wish him all the best in his next chapter." "I am excited to join Carisma's Board and collaborate with the management team as the Company advances its mission to deliver innovative immunotherapies to patients facing serious diseases," said Ms. Cheng. "I look forward to sharing my insights and supporting the Company's strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond." About Sohanya Cheng, MBA Ms. Cheng brings over 20 years of experience in biopharmaceutical commercialization and research, with a strong focus on oncology. She currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics. Prior to this, she was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals. Ms. Cheng also spent over a decade at Amgen in various leadership roles, including Executive Director, Head of Marketing & Sales for multiple myeloma and Head of Oncology National Sales, contributing to the commercialization of key oncology brands. She holds an MBA from the MIT Sloan School of Management and both a BSc and MA from the University of Cambridge, UK. About Carisma Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit . Investors: Shveta Dighe Head of Investor Relations [email protected] Media Contact: Julia Stern (763) 350-5223 [email protected] SOURCE Carisma Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

By integrating patient data with AI/ML technologies, the research team aims to tackle challenging diseases impacting the kidneys and lungs. Credit: mi_viri/Shutterstock. GSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge University Hospitals to expedite immune-related disease research and development (R&D). The five-year partnership, which builds on their existing scientific partnership, will be known as the Cambridge-GSK Translational Immunology Collaboration. Its focus will be on refining the treatment of immune-related diseases with current therapies and accelerating the creation of new ones. This will be achieved by deepening GSK’s research into disease mechanisms, progression, patient response and the development of translational biomarkers. The collaboration will specifically target respiratory and kidney diseases. Cambridge University Hospitals will play a crucial role in the partnership, with the Royal Papworth Hospital also expected to join as a partner. See Also: Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients The Cambridge Biomedical Campus will be instrumental in most of the partnership’s activities related to research, and provides an environment that combines academia, healthcare and industry backed by the National Institute for Health and Care Research Cambridge Biomedical Research Centre. GSK chief scientific officer Tony Wood stated: “Collaboration is at the heart of scientific progress and is fundamental to how we do R&D at GSK. We’re excited to build on our existing work with the University of Cambridge to further this world-leading scientific and technological capability in the UK. “By bringing together Cambridge’s expertise and our own internal capabilities, including an understanding of the immune system and the use of AI to accelerate drug development, we have an opportunity to help patients struggling with complex disease.” The collaboration will adopt a “translational” approach, centred around patients and utilising AI and machine learning (ML). By integrating patient data with AI/ML technologies, the research team aims to tackle challenging diseases impacting the kidneys and lungs. In November 2023, Cambridge University’s spin-out T-Therapeutics raised £48m ($59.7m) in Series A financing to develop T cell receptor therapies.

Plus, news about Takeda, Foresee Pharmaceuticals and Capricor Therapeutics: GSK, Cambridge University team up on immune diseases: The UK drugmaker is pouring £50 million ($65 million) into a five-year partnership with the university and its hospitals to advance R&D for respiratory and kidney disease treatments. The collaboration will make use of AI and machine learning, with a focus on traditionally challenging indications. — Ayisha Sharma Angelini Pharma signs licensing deal with Korean biotech: The deal covers a Cureverse program called CV-01, which is an Nrf2 agonist designed to treat “a range of brain health disorders, including epilepsy.” Cureverse will get an undisclosed upfront payment and can receive up to $360 million in milestones as well as additional royalties. The deal covers global rights outside of South Korea, China, Hong Kong, Macau and Taiwan. — Max Gelman Takeda announces more layoffs in Massachusetts: The workforce reduction will impact 45 employees in Cambridge and 34 in Lexington, according to a WARN notice filed last week. Takeda has already laid off hundreds of employees in the state this year, including 641 in May and another 220 in July . The company declined to comment on the types of roles impacted. — Nicole DeFeudis Foresee Pharmaceuticals touts early topline data for MMP-12 inhibitor: Healthy patients taking the inhibitor, called linvemastat, saw no serious adverse events, and the most common treatment-emergent adverse events were mild nausea and headaches. The company expects to start Phase 2 studies in asthma and inflammatory bowel disease next year. — Katherine Lewin Capricor Therapeutics brought in $86.3 million from a public offering, up from the $75 million it planned to raise. — Jaimy Lee